Profile data is unavailable for this security.
About the company
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. The Company is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its HD program is focused on the development of a potentially disease-modifying treatment for HD.
- Revenue in USD (TTM)0.00
- Net income in USD-58.67m
- Incorporated2017
- Employees57.00
- LocationDesign Therapeutics Inc6005 Hidden Valley Road, Suite 110CARLSBAD 92011United StatesUSA
- Phone+1 (858) 293-4900
- Fax+1 (302) 636-5454
- Websitehttps://www.designtx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Generation Bio Co | 9.96m | -169.06m | 234.85m | 174.00 | -- | 1.78 | -- | 23.57 | -2.56 | -2.56 | 0.1509 | 1.99 | 0.0278 | -- | 10.98 | 57,258.62 | -47.14 | -36.96 | -50.75 | -39.21 | -- | -- | -1,696.87 | -8,879.44 | -- | -- | 0.00 | -- | -- | 177.31 | 7.34 | -- | 19.61 | -- |
Boundless Bio Inc | -100.00bn | -100.00bn | 236.18m | 72.00 | -- | -- | -- | -- | -- | -- | -- | 4.79 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.70 | -- | -- | -- |
G1 Therapeutics Inc | 84.04m | -30.59m | 237.88m | 100.00 | -- | 8.57 | -- | 2.83 | -0.6146 | -0.6146 | 1.55 | 0.531 | 0.6367 | 0.4852 | 6.07 | 840,410.00 | -23.18 | -47.06 | -30.95 | -52.64 | 91.89 | -- | -36.40 | -268.59 | 2.55 | -3.31 | 0.6084 | -- | 60.84 | -- | 67.49 | -- | -- | -- |
Eliem Therapeutics Inc | 0.00 | -14.53m | 238.55m | 9.00 | -- | 2.14 | -- | -- | -0.5347 | -0.5347 | 0.00 | 3.84 | 0.00 | -- | -- | 0.00 | -12.55 | -- | -13.00 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
Coherus Biosciences Inc | 301.87m | -59.29m | 238.63m | 249.00 | -- | -- | -- | 0.7905 | -0.7801 | -0.7801 | 2.86 | -0.7211 | 0.5178 | 3.17 | 1.71 | 986,506.60 | -10.17 | -21.43 | -23.51 | -29.32 | 41.46 | 79.01 | -19.64 | -36.56 | 1.05 | -3.87 | 1.21 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
Chromadex Corp | 83.17m | -3.53m | 238.70m | 106.00 | -- | 8.20 | -- | 2.87 | -0.047 | -0.047 | 1.11 | 0.3852 | 1.54 | 2.66 | 10.01 | 784,594.30 | -6.54 | -42.11 | -10.08 | -65.14 | 60.98 | 59.68 | -4.24 | -30.64 | 1.88 | -- | 0.0007 | -- | 15.99 | 21.50 | 70.15 | -- | -36.66 | -- |
Aldeyra Therapeutics Inc | 0.00 | -30.01m | 239.44m | 10.00 | -- | 2.11 | -- | -- | -0.5080 | -0.5080 | 0.00 | 1.91 | 0.00 | -- | -- | 0.00 | -19.39 | -36.79 | -22.08 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1182 | -- | -- | -- | 39.47 | -- | -- | -- |
Codexis Inc | 74.23m | -65.13m | 239.90m | 174.00 | -- | 3.03 | -- | 3.23 | -0.9412 | -0.9412 | 1.07 | 1.12 | 0.4039 | 5.92 | 4.34 | 426,632.20 | -35.43 | -17.13 | -43.38 | -20.23 | 82.29 | 77.29 | -87.73 | -37.04 | 3.63 | -- | 0.2617 | -- | -49.39 | 2.97 | -126.96 | -- | 9.80 | -- |
Akebia Therapeutics Inc | 187.23m | -43.03m | 241.04m | 167.00 | -- | -- | -- | 1.29 | -0.2213 | -0.2213 | 0.9726 | -0.1301 | 0.7454 | 1.40 | 8.43 | 1,121,108.00 | -17.13 | -37.42 | -24.39 | -56.00 | 82.75 | 69.13 | -22.98 | -82.25 | 1.31 | -5.00 | 10.44 | -- | -33.46 | -1.30 | 44.89 | -- | -- | -- |
Pyxis Oncology Inc | 16.15m | -57.80m | 246.74m | 51.00 | -- | 1.34 | -- | 15.28 | -1.39 | -1.39 | 0.368 | 3.13 | 0.0801 | -- | -- | 322,920.00 | -28.68 | -- | -30.64 | -- | 97.06 | -- | -358.00 | -- | -- | -- | 0.00 | -- | -- | -- | 38.87 | -- | -- | -- |
Century Therapeutics Inc | 1.37m | -133.47m | 248.54m | 152.00 | -- | 1.09 | -- | 181.42 | -2.22 | -2.22 | 0.0227 | 2.74 | 0.0034 | -- | -- | 9,013.16 | -33.17 | -- | -35.08 | -- | -- | -- | -9,742.41 | -- | -- | -- | 0.00 | -- | -57.01 | -- | -4.38 | -- | -- | -- |
Design Therapeutics Inc | 0.00 | -58.67m | 248.58m | 57.00 | -- | 0.9222 | -- | -- | -1.05 | -1.05 | 0.00 | 4.77 | 0.00 | -- | -- | 0.00 | -19.44 | -- | -19.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.61 | -- | -- | -- |
Metagenomi Inc | 44.76m | -68.26m | 250.69m | 236.00 | -- | -- | -- | 5.60 | -1.82 | -1.82 | 1.19 | 5.73 | -- | -- | -- | 189,644.10 | -- | -- | -- | -- | -- | -- | -152.50 | -- | -- | -- | 0.00 | -- | 160.21 | -- | -56.57 | -- | -- | -- |
Foghorn Therapeutics Inc. | 33.90m | -92.95m | 255.51m | 116.00 | -- | -- | -- | 7.54 | -2.21 | -2.21 | 0.8046 | -2.29 | 0.108 | -- | -- | 292,206.90 | -29.61 | -31.35 | -35.75 | -35.69 | -- | -- | -274.23 | -777.33 | -- | -- | -- | -- | 77.63 | -- | 9.60 | -- | -4.50 | -- |
XBiotech Inc | 0.00 | -30.74m | 260.11m | 92.00 | -- | 1.24 | -- | -- | -1.01 | -1.01 | 0.00 | 6.87 | 0.00 | -- | -- | 0.00 | -13.08 | 31.88 | -13.68 | 33.27 | -- | -- | -- | 877.30 | -- | -- | 0.0456 | 0.00 | -100.00 | -- | 25.36 | -- | 24.30 | -- |
Holder | Shares | % Held |
---|---|---|
Logos Global Management LPas of 31 Mar 2024 | 5.03m | 8.91% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 2.01m | 3.55% |
Baker Bros. Advisors LPas of 31 Mar 2024 | 1.66m | 2.94% |
Tang Capital Management LLCas of 31 Mar 2024 | 1.48m | 2.62% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 1.26m | 2.23% |
Almitas Capital LLCas of 31 Mar 2024 | 1.03m | 1.82% |
BML Capital Management LLCas of 31 Mar 2024 | 879.48k | 1.56% |
Citadel Advisors LLCas of 31 Mar 2024 | 851.98k | 1.51% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 698.99k | 1.24% |
Geode Capital Management LLCas of 31 Mar 2024 | 683.90k | 1.21% |